» Articles » PMID: 27378422

Sirtuin1 Promotes Osteogenic Differentiation Through Downregulation of Peroxisome Proliferator-activated Receptor γ in MC3T3-E1 Cells

Overview
Publisher Elsevier
Specialty Biochemistry
Date 2016 Jul 6
PMID 27378422
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoporosis is a skeletal disorder characterized by bone loss, resulting in architectural deterioration of the skeleton, decreased bone strength and an increased risk of fragility fractures. Strengthening osteogenesis is an effective way to relieve osteoporosis. Sirtuin1 (Sirt1) is a nicotinamide adenine dinucleotide (NAD(+))-dependent deacetylase, which is reported to be involved in improving osteogenesis. Sirt1 targets peroxisome proliferator-activated receptor γ (PPARγ) in the regulation of adipose tissues; however, the molecular mechanism of Sirt1 in osteogenic differentiation is still unknown. PPARγ tends to induce more adipogenic differentiation rather than osteogenic differentiation. Hence, we hypothesized that Sirt1 facilitates osteogenic differentiation through downregulation of PPARγ signaling. Mouse pre-osteoblastic MC3T3-E1 cells were cultured under osteogenic medium. Sirt1 was overexpressed through plasmid transfection. The results showed that high expression of Sirt1 was associated with increased osteogenic differentiation, as indicated by quantitative PCR and Western blot analysis of osteogenic markers, and Von Kossa staining. Sirt1 overexpression also directly and negatively regulated the expression of PPARγ and its downstream molecules. Use of the PPARγ agonist Rosiglitazone, reversed the effects of Sirt1 on osteogenic differentiation. Using constructed luciferase plasmids, we demonstrated a role of Sirt1 in inhibiting PPARγ-induced activity and expression of adipocyte-specific genes, including acetyl-coenzyme A carboxylase (Acc) and fatty acid binding protein 4 (Fabp4). The interaction between Sirt1 and PPARγ was further confirmed using co-immunoprecipitation analysis. Together, these results reveal a novel mechanism for Sirt1 in osteogenic differentiation through downregulation of PPARγ activity. These findings suggest that the Sirt1-PPARγ pathway may represent a potential target for enhancement of osteogenesis and treatment of osteoporosis.

Citing Articles

Sirtuins mediate mitochondrial quality control mechanisms: a novel therapeutic target for osteoporosis.

Zhang T, Wang L, Duan X, Niu Y, Li M, Yun L Front Endocrinol (Lausanne). 2024; 14:1281213.

PMID: 38264287 PMC: 10805026. DOI: 10.3389/fendo.2023.1281213.


microRNA-29b-3p/sirtuin-1/peroxisome proliferator-activated receptor γ suppress osteogenic differentiation.

Xie H, Cao L, Ye L, Li Q, Zhang Y, Zhang H In Vitro Cell Dev Biol Anim. 2023; 59(2):109-120.

PMID: 36881345 DOI: 10.1007/s11626-023-00753-7.


Melatonin suppresses bone marrow adiposity in ovariectomized rats by rescuing the imbalance between osteogenesis and adipogenesis through SIRT1 activation.

Huang X, Chen W, Gu C, Liu H, Hou M, Qin W J Orthop Translat. 2022; 38:84-97.

PMID: 36381247 PMC: 9619141. DOI: 10.1016/j.jot.2022.10.002.


Role of histone modification in the occurrence and development of osteoporosis.

Sun P, Huang T, Huang C, Wang Y, Tang D Front Endocrinol (Lausanne). 2022; 13:964103.

PMID: 36093077 PMC: 9458911. DOI: 10.3389/fendo.2022.964103.


Targeting Sirt1, AMPK, Nrf2, CK2, and Soluble Guanylate Cyclase with Nutraceuticals: A Practical Strategy for Preserving Bone Mass.

McCarty M, Lewis Lujan L, Iloki Assanga S Int J Mol Sci. 2022; 23(9).

PMID: 35563167 PMC: 9104509. DOI: 10.3390/ijms23094776.